Glaxo Halts Red Wine Drug Study Enrollment on Concern About Kidney Damage

GlaxoSmithKline Plc suspended enrollment in a study of a drug designed to mimic the benefits of red wine after kidney damage developed in some patients with multiple myeloma.

Glaxo acquired the compound known as SRT501 with the $720 million purchase of Sirtris Pharmaceuticals Inc. two years ago. The study is being done to evaluate the safety of the treatment alone and in combination with Takeda Pharmaceutical Co.’s Valcade. Five of 24 patients in the trial developed cast nephropathy, a type of kidney damage that can stem from multiple myeloma and lead to organ failure, said Jo Revill, a spokeswoman for the London-based drugmaker.

Glaxo previously completed two studies of the drug in diabetics and saw no signs of the complication, Revill said today in a telephone interview. The company notified researchers, patients and regulators about the findings and is reviewing all the available information. While some patients elected to continue in the trial, no volunteers are being added, Revill said.

The study may resume depending on what the investigators find, Revill said. The drug is in development for a range of conditions, including Alzheimer’s disease, obesity, and cancer treatment and prevention.

To contact the reporter on this story: Michelle Fay Cortez in London at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.